Lentigen has named Adam Sachs to the newly created position of president of commercial operations, where he will lead efforts to market the firm’s lentiviral platform, the company said.
Sachs comes to Lentigen having spent 15 years in the biotech field, most recently as a molecular biology product development executive at Life Technologies, which is now Invitrogen.
Sachs also was director of manufacturing at Qiagen and vice president of operations at OriGene Technologies.
The Analytical and Life Science Systems Association, a trade group for product makers and marketers in the life sciences, has appointed Eksigent president and CEO David Weber to its board of directors, Eksigent said.
Before joining Eksigent, Weber served as vice president of global marketing and business development for Stratagene and was president of the Americas at Amersham Biosciences.
Rik van Heijningen has been named vice president of commercial operations for genomics and proteomics at Kreatech, the Dutch biotechnology company said last week.
According to Kreatech, van Heijningen will focus on corporate and business development for the firm’s protein, gene expression, and array comparative genomic hybridization reagent kits.
Prior to joining Kreatech, van Heijningen held several sales and marketing positions with Dynal Biotech and Invitrogen in Norway, Germany, and the Netherlands.